HilleVax(US:HLVX)2025-03-28 21:05Financial Performance - The net loss for the year ended December 31, 2024, was $147.3 million, compared to a net loss of $123.6 million for the year ended December 31, 2023, indicating an increase in net loss of approximately 19.2%[6][12] - Total operating expenses for the full year ended December 31, 2024, were $155.3 million, up from $133.3 million in 2023, representing an increase of approximately 16.5%[12] - Research and development expenses for the full year ended December 31, 2024, were $78.2 million, a decrease of 26.7% compared to $106.7 million for the full year ended December 31, 2023[3][12] - General and administrative expenses for the full year ended December 31, 2024, increased to $28.8 million from $26.7 million in 2023, reflecting an increase of approximately 7.8%[4][12] - The company reported other income of $8.0 million for the full year ended December 31, 2024, down from $9.8 million in 2023, a decrease of approximately 18.4%[5][12] Assets and Liabilities - The company’s total assets decreased to $192.7 million as of December 31, 2024, from $344.4 million as of December 31, 2023, a decline of approximately 44.9%[14] - Total liabilities decreased to $38.2 million as of December 31, 2024, from $78.9 million in 2023, a reduction of approximately 51.6%[14] - The company’s total stockholders' equity decreased to $154.5 million as of December 31, 2024, from $265.5 million in 2023, a decrease of approximately 41.8%[14] Strategic Development - The company is exploring continued development of its norovirus vaccine candidates and other strategic alternatives[1] Cash and Marketable Securities - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $171.4 million, down from $303.5 million as of December 31, 2023, representing a decrease of approximately 43.5%[2][14]